Novartis aims to pump up cardio business with Ionis deal

Novartis on Monday exercised its option to license an RNA-targeting cardiovascular drug from Ionis Pharmaceuticals as the Swiss company aims to surround its heart-failure blockbuster Entresto with other medicines.